Celera Corp., a laboratory testing products and disease management services company, said Wednesday a hefty charge related to its split from Applera Corp. widened the company's fiscal 2008 fourth-quarter loss.
For the period ended June 30, the company lost $96.8 million, or $1.21 per share, compared with a loss of $8 million, or 10 cents per share, a year prior. Excluding about $96 million in charges, the company's loss narrowed to 1 cent per share.
Meanwhile, revenue quadrupled to $43.4 million from $10.2 million, mainly because of products from Berkeley HeartLab Inc. and Atria Genetics. Both companies were bought in the fiscal fourth quarter.
Analysts polled by Thomson Financial expected the company to break even on $41.9 million in revenue.
For the fiscal year ended June 30, the company lost $103.2 million, or $1.30 per share, compared with a loss of $20.6 million, or 26 cents per share, during the same period a year prior. Revenue rose to $139.4 million from $43.4 million.
Excluding charges, the company met its goal of ending the fiscal year on a profitable note, with 1 cent per share.
"The quarter's operating performance was good, closing out a solid fiscal 2008 _ a pivotal year for Celera," said Chief Executive Kathy Ordonez, in a statement. "The business developed as planned, as we achieved our annual financial goals for revenue and profitability on a non-GAAP basis."
Looking ahead, the company plans to align its fiscal year with the regular calendar year. As part of the process, the company issued its outlook for the remaining six months of the calendar year.
It expects low, single-digit earnings per share on an adjusted basis, with revenue between $88 million and $93 million.
Shares of Celera fell 9 cents to $13.28 in after-hours trading after falling 6 cents to close at $13.37 during the regular trading session.
Terms & Conditions
RSS Headlines
Fool UK